U.S. drills completed masking and isolation together in 60% of 73 outbreak simulations
In CDC’s January–June simulations, median time to masking was 2 minutes and to isolation 11 minutes.
Follow global economy, business, finance, energy, climate and public affairs through original sources, sourced data and context.
In CDC’s January–June simulations, median time to masking was 2 minutes and to isolation 11 minutes.
Diagnostic imaging company Bracco announced that more than 6 million intravenous doses of VUEWAY (gadopiclenol) have been administered worldwide since its initial 2022 approval, following 2026 EU and U.S. pediatric extensions to term neonates and infants. The release also highlights the Max 3 injector and AiMIFY software, without disclosing product sales revenue.
Johnson & Johnson announced on 20 November 2026 that TREMFYA met primary and major secondary endpoints at Week 24 in the 411-patient Phase 4 STAR study of axial psoriatic arthritis, reducing BASDAI scores and MRI-assessed sacroiliac inflammation versus placebo.
PAQ Therapeutics reported on 20 November 2026 preliminary Phase 1 results for its selective KRAS G12D degrader PT0253 in advanced solid tumors, showing no dose-limiting toxicities across 10 to 750 mg and early responses in monotherapy and first-line pancreatic cancer.
HHS and ASPE analyses show lower prescription opioid dispensing and more patients filling two treatment medications, while leaving mortality causes unresolved.